BioCentury
ARTICLE | Product Development

Nabi chronicles

November 7, 2005 8:00 AM UTC

Last Tuesday's announcement that NABI was halting development of its StaphVax vaccine sent the stock into a freefall; it dropped $8.35 (71%) to $3.40 on the week. Additionally, NABI said it would halt...